RAC 2.92% $1.94 race oncology ltd

Ann: Race Initiates FTO Directed Kidney Cancer Preclinical Study, page-14

  1. 1,313 Posts.
    lightbulb Created with Sketch. 270
    Far from minor, just shows how the average punter doesn't get it.

    "The results of this study will support Phase II human trials of Bisantrene in ccRCC, currently
    scheduled to begin in Australia in early 2022."
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.